By June M. McKoy, Md, MPH1, Karen A. Fitzner, PhD2, Beatrice J. Edwards, MD3, Motasem Alkhatib, MD4, Cara C. Tigue, BA5, Narissa J. Nonzee, BS6, Carlos R. Bolden, BS7, Charles L. Bennett, MD, PhD, MPP8 |
June 1, 2007
The authors appreciate Eric Schmid's development of the targeted drug cost table (Table 1).
This article is part on an ongoing series, Your Older Patient, which is guest edited by Lodovico Balducci, md, Professor of Oncology and Medicine, and Director of the Division of Geriatric Oncology, University of South Florida College of Medicine and H. Lee Moffitt Cancer Center, Tampa, Florida.
1. American Cancer Society: Cancer facts and figures 2006. Available at www.cancer.org/docroot/STT/stt_0_2006.asp. Accessed February 1, 2007.
2. Brown ML, Lipscomb J, Snyder C: The burden of illness of cancer: Economic cost and quality of life. Annu Rev Pub Health 22:91-113, 2001.
3. Brown ML, Riley GF, Schulsser N, et al: Estimating health care costs related to cancer treatment from SEER-Medicare data. Medical Care 40(8 suppl):IV-104-IV-117, 2002.
4. SEER Cancer Statistics Review 1975-2003: Estimated new cancer cases and deaths for 2006 (Table I-1). Available at seer.cancer.gov/csr/1975_2003/results_single/sect_01_table.01.pdf. Accessed December 19, 2006.
5. American Cancer Society: Cost of cancer on the rise. ACS News Center. Available at www.cancer.org/docroot/NWS/content/NWS_1_1x_Cost_of_Cancer_On_the_Rise.asp. Accessed December 16, 2006.
6. Balducci L, Lyman GH: Cancer in the elderly: Epidemiologic and clinical implications. Clin Geriatr Med 13:1-14, 1997.
7. Hayman JA, Langa KM, Kabeto MU, et al: Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol 19:3219-3225, 2001.
8. US Census Bureau: Available at www.census.gov. Accessed February 12, 2007.
9. Harlan LC, Greene AL, Clegg LX, et al: Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol 23:9079-9088, 2005.
10. Stuart B, Briesacher BA, Shea DG, et al: Riding the rollercoaster: The ups and downs in out-of-pocket spending under the standard Medicare drug benefit. Health Aff 24:1022-1031, 2005.
11. Berenson A: A cancer drug shows promise, at a price that many can't pay. New York Times February 15, 2006. Available at www.nytimes.com/2006/02/15/business/15drug.html?ei=5090&en=62aabaec5acffa8. Accessed December 7, 2006.
12. SegotaE, Bukowski RM: The promise of targeted therapy: Cancer drugs become more specific. Cleve Clin J Med 71(7):551-60, 2004.
13. Bicknell R: The realisation of targeted antitumour therapy. Br J Cancer 92(suppl 1):S2-S5, 2005.
14. Tigue CC, Fitzner KA, Alkhatib M, et al: The value of innovation: The economics of targeted drugs for cancer. Targeted Oncology 2:113-119, 2007.
15. Lyman GH, Kuderer NM, Djulbegovic B: Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis. Am J Med 112:406-411, 2002.
16. Repetto L, Biganzoli L, Koehne CH, et al: EORTC Cancer in the Elderly Task Force Guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39:2264-2272, 2003.
17. De Lima M, Giralt S: Allogeneic transplantation for the elderly patient with acute myelogenous Leukemia or myelodysplastic syndrome. Semin Hematol 43:107-117, 2006.
18. Calhoun EA, Bennett CL: Evaluating the total costs of cancer: The Northwestern University Costs of Cancer Program. Oncology (Williston Park) 17:109-114, 2003.
19. National Cancer Institute: Estimates of national expenditures for medical treatment for the 15 most common cancers (Table L2). Cancer Trends Progress Report-2005 Udpate. Available at progressreport.cancer.gov/doc_detail.asp?pid=1&did=2005&chid=25&coid=226&mid=. Accessed April 18, 2007.
20. Yabroff KR, Davis WW, Lamont EB, et al: Patient time costs associated with cancer care. J Natl Cancer Inst 99:14-23, 2007.
21. Wilson LS, Tesoro R, Elkin EP, et al: Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109:518-527, 2007.
22. Schrag D: The price tag on progress—chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004.
23. Stephens JM, Gramegna P, Laskin B, et al: Chronic lymphocytic Leukemia: Economic burden and quality of life (literature review). Am J Ther 12:460-466, 2005.
24. Agency for Healthcare Research and Quality: Care of Women in US Hospitals, 2000. HCUP Fact Book No. 3. AHRQ publication no. 02-0044, October 2002. Available at www.ahrq.gov/data/hcup/factbk3/factbk3.htm. Accessed February 26, 2007.
25. Bennett CL, Schumock GT: Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia: Can they improve clinical decision making? Drugs Aging 20:479-483, 2003.
26. Lang K, Menzin J, Earle CC, et al: The economic cost of squamous cell cancer of the head and neck: Findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg 130:1269-1275, 2004.
27. Ramsey SD, Howlader N, Etzioni RD, et al: Chemotherapy use, outcomes, and costs for older persons with advanced non-small cell lung cancer: Evidence from Surveillance, Epidemiology and End Results—Medicare. J Clin Oncol 22:4971-4978, 2004.
28. Langa KM, Fendrick AM, Chernew ME, et al: Out-of-pocket health-care expenditures among older americans with cancer. Value Health 7:186-194, 2004.
29. Arozullah AM, Calhoun EA, Wolf M, et al: The financial burden of cancer: Estimates from a study of insured women with breast cancer. J Support Oncol 2:271-278, 2004.
30. McKoy JM, Weitner BB, Fitzner KA, et al: Cost and burden of cancer: A comparison of breast, prostate, colorectal, lung and head and neck cancer. Under review.
31. Bennett CL, Weinberg PD, Lieberman JJ: Cancer insurance policies in Japan and the United States. West J Med 168:17-22, 1998.
32. Reeder CE, Gordon D: Managing oncology costs. Am J Manag Care 12(suppl):S3-S19 (incl quiz). Available at www.ajmc.com/viewIssue.cfm?ID=2034. Accessed December 20, 2006.
33. American Cancer Society: Making a Part D plan decision. Available at www.cancer.org/docroot/MIT/content/MIT_3_1_Making_a_Plan_Decision.asp?sitearea=MIT. Accessed December 20, 2006.
34. Unger JM, Coltman CA Jr, Crowley JJ, et al: Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 24:141-144, 2006.
35. Hutchins LF, Unger JM, Crawley CA, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999.
36. Talarico L, Chen G, Pazdur R: Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol 22:4626-4631, 2004.
37. Bugeja G, Kumar A, Banerjee AK: Exclusion of elderly people from clinical research: A descriptive study of published reports. BMJ 315:1059, 1997.
38. National Cancer Institute: Clinical trials covered under the Medicare anti-cancer drugs national coverage decision. Available at www.cancer.gov/clinicaltrials/developments/NCD179N. Accessed December 19, 2006.
39. Centers for Medicare and Medicaid Services: Medicare coverage—clinical trials. Provider Bulletin. Available at www.cms.hhs.gov/ClinicalTrialPolicies/Downloads/providerbulletin.pdf. Accessed December 15, 2006.
40. Suda KJ, Motl SE, Kuth JC: Inpatient oncology length of stay and hospital costs: Implications for rising inpatient expenditures. J Appl Res 6:126-131, 2006.
41. Chang S, Long SR, Kutikova L, et al: Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 22:3524-3530, 2004.